RFA-CA-25-002-Full-Announcement.html

This Request for Applications (RFA-CA-25-002) from the National Cancer Institute (NCI) seeks R33 grant applications for advanced development and validation of emerging molecular and cellular analysis technologies for cancer research. The funding opportunity supports projects where major feasibility gaps have been overcome with preliminary data, but further development and validation are needed for adoption by the research community.

The grant is administered by the Department of Health and Human Services/National Institutes of Health under the Cancer Detection and Diagnosis Research program (CFDA 93.394). Eligible applicants include higher education institutions, nonprofits, small businesses, tribal organizations, and various government entities. Projects must focus on technologies that enhance molecular/cellular characterization of cancer for applications in biology, early detection, diagnosis, treatment, epidemiology, or health disparities. The opportunity specifically excludes projects that merely apply existing technologies to new biological targets. This RFA is part of NCI's Innovative Molecular Analysis Technologies (IMAT) Program.